Share Name Share Symbol Market Type Share ISIN Share Description
Bioventix LSE:BVXP London Ordinary Share GB00B4QVDF07 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 1,925.00p 1,900.00p 1,950.00p 1,925.00p 1,925.00p 1,925.00p 2,263 06:30:08
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 5.5 4.2 69.2 27.8 98.15

Bioventix Share Discussion Threads

Showing 551 to 575 of 575 messages
Chat Pages: 23  22  21  20  19  18  17  16  15  14  13  12  Older
DateSubjectAuthorDiscuss
22/7/2017
10:42
Slightly dated article looking at developments in automated CSF assays (Http://www.alzforum.org/news/conference-coverage/are-csf-assays-finally-ready-prime-time). According to the article, Roche, Fujirebio and Euroimmun are introducing automated, CE marked CSF assays for beta amyloid 1-42 (and others) in 2017. Fujirebio is in the market in Europe already, Roche supposedly June and Euroimmun (now owned by Perkin-Elmer) later in the year. Euroimmun are using an antibody developed by Adx Neurosciences (Http://www.adxneurosciences.com/en/pipeline) who also appear to be well advanced with a blood test. Fujirebio looks to be using an antibody from Eli Lilly ("a license for the use of amyloid beta monoclonal antibodies contained in this product under patents US 6114133, US7811769, and EP 0792458 has been obtained from Eli Lilly" from Https://www.fujirebio-europe.com/products-services/product-browser/innotestr-v-amyloid1-42). Roche unclear. Article also notes issues with generating consistent results.
gsbmba99
21/7/2017
07:53
The Alzheimers Association International Conference just concluded in London (Https://www.alz.org/aaic/releases_2017/AAIC17-Wed-briefing-Developing-Topcis.pdf). Go to Blood Biomarker for Amyloid Plaques. Dr. Bateman: “We’re excited because the results also suggest that blood-derived amyloid-beta may be useful as a rapid and inexpensive screening test for brain amyloidosis, and may be able to identify people who are at higher risk of Alzheimer’s disease very early in the process.” ... "Having a simple and inexpensive blood test for screening is likely to greatly accelerate clinical trials to find Alzheimer’s drugs. And, it could facilitate widespread treatment when effective anti-amyloid therapeutics are developed,” Bateman added. Not directly related to BVXP as I think it's a different test but useful in the ongoing effort to establish clinical usefulness of blood based beta amyloid testing.
gsbmba99
10/7/2017
13:47
Yes. There's clearly a village somewhere missing it's idiot. If Opodia tells us where he is, we can let them know so that they can come and collect him....;-)
ilovefrogs
10/7/2017
13:45
Ilovefrogs....you are nearly right...I think he has two neurons ,unfortunately one is inhibitory.
tadders2
10/7/2017
13:22
Hi Opodio my single-brain celled friend - Please do explain how a firm which specializes in the development of sheep monoclonal antibodies for use in immunodiagnostics and clinical testing faces competition from generics. Do that, and perhaps we'll take you seriously! I thin you have your work cut out though........
ilovefrogs
09/7/2017
19:59
You need to sell too CC - otherwise Opodio will have to take his shorts off, and that's not a pretty sight.
trident5
09/7/2017
19:38
"A generic rival launch" LOL! You clearly have no idea about the BVXP business model.
crazycoops
09/7/2017
13:26
So insightful. I must sell my shares tomorrow.
trident5
09/7/2017
13:05
Reckon there be a generic rival launch which will kill the business
opodio
09/7/2017
13:03
What a lot of nonsense
tadders2
09/7/2017
12:57
Profit warning coming I suspect this will fall to 6 pounds Don't forget there were massive Director sales End of last year they know party is over
opodio
07/7/2017
11:43
tree shake?
melody9999
14/6/2017
18:12
Https://www.hindawi.com/journals/dm/2017/4523096/ Very technical write-up of the transition from TnI to hsTnI at an Italian hospital using the Abbott test.
gsbmba99
14/6/2017
17:48
Http://heart.bmj.com/content/103/Suppl_5/A52.1 "The introduction of hsTnI has not resulted in a shorter length of hospital stay for patients undergoing troponin testing. Troponin testing became more frequent after the introduction of the new assay which may have resulted in extra, unnecessary admissions." An unsurprising conclusion given: "All patients who had 2 hsTnI requests ended up being admitted to hospital, even if both were undetectable." Seems unusually conservative to admit everyone with two sequential undetectable hsTnI tests given the sensitivity of the test. Potentially more relevant longer term: "No patient who had an undetectable 1st troponin had a positive 2nd troponin."
gsbmba99
09/6/2017
10:18
Er, it has been going up.
trident5
09/6/2017
09:36
With the £ weak, resulting in more profits, for this company, this share price should be going up not down on account of the pound? In any event, this company is not threatened by any outside factors or are the Chinese commencing their unique tests and swamping the market with their cheap processes? This should be going up not down!
a1samu
26/5/2017
13:29
I like the chart
remarkomsoc
17/5/2017
11:41
Pre-Diagnostics presented at the same conference last year as Cardinor. The presentation is here (Https://www.b2match.eu/system/ssbbs2016/files/A1_9_PreDiagnostics.pdf?1455895575) Presentation not as detailed as Cardinor and no timelines. Their test seems to be positioned as a lower cost, less invasive test than CSF (cerebrospinal fluid) or PET scan. Reference to IVD test cost of US$200 vs $3-5k+ for other methods.
gsbmba99
11/5/2017
15:38
Maybe Valhamos, although it did rise pretty soon after the split, prior to the trading update. I agree with the general theme here though, splits shouldn't make any difference whatsoever but investor psychology is a funny old thing. ilovefrogs - good point about about US stocks being valued in $ rather than in the UK where we use pence.
crazycoops
11/5/2017
15:23
Stock splits in the US are genuinely needed if a Company wants to continue to attract retail investors. Take Apple's 7 for 1 split in 2014 - at that time, the stock price was $600, which would actually preclude a meaningful number of smaller investors who wouldn't want a sum of this size exposed to a single Company. This is less of an issue in the UK, where the highest price that most stocks go to is in tens of pounds rather than 100s like the US. Astra seems quite happy with it's ~£50 price. On balance, I wouldn't expect BVXP to feel the need for a split here, and frankly, I don't give a monkeys either way! GLA
ilovefrogs
11/5/2017
14:15
The share price increase at AIR I would suggest would have happened regardless of the share split in January and in fact it was increasing out of its range from August 2016 (when I made my last purchase and I still hold) as a result of a strongly positive trading update.
valhamos
11/5/2017
13:55
A recent example of the share split paradox is with AIR. They were c£5 when they split 5/1 and were also stuck in a tight trading range for several months. After the share split, voila! More volume, more liquidity and for now at least a c20% rise. For the record, I've sold out if AIR now, not because of the split but because of only a lukewarm belief in the business.I'm agnostic about a split for BVXP. It's my largest holding and although I like to top slice from time to time, I am holding for the very long-term as long as their superb business model continues to deliver and they keep paying a rising dividend based on rising eps and cash generation. In a way, I like that it is a relatively "quiet" share that I don't need to worry about. If they did a share split it would likely lead to more short-term gains but with a lot more noise.
crazycoops
11/5/2017
13:43
http://www.healio.com/cardiology/vascular-medicine/news/print/cardiology-today/%7B1b05eb44-de1c-4edc-8abf-652df6aacf37%7D/high-sensitivity-troponin-assays-present-opportunities-challenges-for-mi-diagnosis
boros10
11/5/2017
13:39
I'd prefer that this superbly run company doesn't waste our money on the costs of silly share splits.But ask me again at £100.
igbertsponk
11/5/2017
13:21
There is sufficient evidence to confirm that when a share price rises to the levels we are seeing with BVXP that a share-split does indeed attract new investors. It happens more frequently in America where the stock (shares in British parlance) price alone can be used as a rough and ready valuation tool against other stocks within the same sectors. Is it logical? Perhaps not. Personally I do not much like share-splits as it appears to result in more volatility which I dislike. Still, if investing was all about logic then we would not be having so much fun...
carcosa
Chat Pages: 23  22  21  20  19  18  17  16  15  14  13  12  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:33 V: D:20170725 14:48:18